Targeting TBK1 to overcome resistance to cancer immunotherapy

被引：87

作者：

Sun, Yi ^{[1
]}

Revach, Or-yam ^{[1
]}

Anderson, Seth ^{[2
]}

Kessler, Emily A. A. ^{[2
]}

Wolfe, Clara H. H. ^{[2
]}

Jenney, Anne ^{[3
]}

Mills, Caitlin E. E. ^{[3
]}

Robitschek, Emily J. J.

Davis, Thomas G. R. ^{[2
]}

Kim, Sarah ^{[2
]}

Fu, Amina ^{[1
]}

Ma, Xiang ^{[1
]}

Gwee, Jia ^{[1
]}

Tiwari, Payal ^{[2
]}

Du, Peter P. P.

Sindurakar, Princy ^{[1
]}

Tian, Jun ^{[1
]}

Mehta, Arnav ^{[1
,2
,4
]}

Schneider, Alexis M. M. ^{[2
,5
]}

Yizhak, Keren ^{[6
]}

Sade-Feldman, Moshe ^{[1
,2
]}

LaSalle, Thomas ^{[1
]}

Sharova, Tatyana ^{[7
]}

Xie, Hongyan ^{[1
]}

Liu, Shuming ^{[3
]}

Michaud, William A. A. ^{[7
]}

Saad-Beretta, Rodrigo ^{[1
]}

Yates, Kathleen B. B. ^{[1
,2
]}

Iracheta-Vellve, Arvin ^{[2
]}

Spetz, Johan K. E. ^{[3
,8
,9
]}

Qin, Xingping ^{[3
,8
,9
]}

Sarosiek, Kristopher A. A. ^{[3
,8
,9
]}

Zhang, Gao ^{[10
,11
,12
]}

Kim, Jong Wook ^{[13
,14
,15
]}

Su, Mack Y. Y. ^{[16
]}

Cicerchia, Angelina M. M. ^{[1
]}

Rasmussen, Martin Q. Q.

Klempner, Samuel J. J.

Juric, Dejan ^{[1
]}

Pai, Sara I. I.

Miller, David M. M.

Giobbie-Hurder, Anita ^{[17
]}

Chen, Jonathan H. H. ^{[1
,2
,18
]}

Pelka, Karin ^{[1
,2
]}

Frederick, Dennie T. T. ^{[1
]}

Stinson, Susanna ^{[19
]}

Ivanova, Elena ^{[4
]}

Aref, Amir R. R.

Paweletz, Cloud P. P.

Barbie, David A. A.

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA

[2] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA

[3] Harvard Med Sch, Harvard Program Therapeut Sci, Lab Syst Pharmacol, Boston, MA 02115 USA

[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[5] MIT, Dept Biol Engn, Cambridge, MA USA

[6] Technion, Inst Technol, Rappaport Fac Med, Dept Cell Biol & Canc Sci, Haifa, Israel

[7] Harvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Dept Surg, Div Surg Oncol, Boston, MA USA

[8] Harvard Sch Publ Hlth, Mol & Integrat Physiol Sci Program, Boston, MA USA

[9] Harvard Sch Publ Hlth, John B Little Ctr Radiat Sci, Boston, MA USA

[10] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA USA

[11] Duke Univ, Preston Robert Brain Tumor Ctr T, Dept Neurosurg, Sch Med, Durham, NC USA

[12] Duke Univ, Preston Robert Tisch Brain Tumor Ctr, Dept Pathol, Sch Med, Durham, NC USA

[13] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA USA

[14] Univ Calif San Diego, Ctr Novel Therapeut, La Jolla, CA USA

[15] Univ Calif San Diego, Dept Med, La Jolla, CA USA

[16] Harvard Med Sch, Boston, MA USA

[17] Dana Farber Canc Inst, Dept Data Sci, Div Biostat, Boston, MA USA

[18] Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA

[19] Gilead Sci, Foster City, CA USA

来源：

NATURE | 2023年 / 615卷 / 7950期

关键词：

EXPRESSION; DESIGN; CELLS; CGAS;

D O I：

10.1038/s41586-023-05704-6

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking(1,2). Here we identify the innate immune kinase TANK-binding kinase 1 (TBK1)(3) as a candidate immune-evasion gene in a pooled genetic screen(4). Using a suite of genetic and pharmacological tools across multiple experimental model systems, we confirm a role for TBK1 as an immune-evasion gene. Targeting TBK1 enhances responses to PD-1 blockade by decreasing the cytotoxicity threshold to effector cytokines (TNF and IFN gamma). TBK1 inhibition in combination with PD-1 blockade also demonstrated efficacy using patient-derived tumour models, with concordant findings in matched patient-derived organotypic tumour spheroids and matched patient-derived organoids. Tumour cells lacking TBK1 are primed to undergo RIPK- and caspase-dependent cell death in response to TNF and IFN gamma in a JAK-STAT-dependent manner. Taken together, our results demonstrate that targeting TBK1 is an effective strategy to overcome resistance to cancer immunotherapy.

引用

页码：158 / +

页数：32

共 64 条

[1] 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade [J].

Aref, Amir R. ;

Campisi, Marco ;

Ivanova, Elena ;

Portell, Andrew ;

Larios, Dalia ;

Piel, Brandon P. ;

Mathur, Natasha ;

Zhou, Chensheng ;

Coakley, Raven Vlahos ;

Bartels, Alan ;

Bowden, Michaela ;

Herbert, Zach ;

Hill, Sarah ;

Gilhooley, Sean ;

Carter, Jacob ;

Canadas, Israel ;

Thai, Tran C. ;

Kitajima, Shunsuke ;

Chiono, Valeria ;

Paweletz, Cloud P. ;

Barbie, David A. ;

Kamm, Roger D. ;

Jenkins, Russell W. .

LAB ON A CHIP, 2018, 18 (20) :3129-3143

[2] INTERFERON-GAMMA AND TUMOR-NECROSIS-FACTOR HAVE A ROLE IN TUMOR REGRESSIONS MEDIATED BY MURINE CD8+ TUMOR-INFILTRATING LYMPHOCYTES [J].

BARTH, RJ ;

MULE, JJ ;

SPIESS, PJ ;

ROSENBERG, SA .

JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (03) :647-658

[3] Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade [J].

Benci, Joseph L. ;

Xu, Bihui ;

Qiu, Yu ;

Wu, Tony J. ;

Dada, Hannah ;

Twyman-Saint Victor, Christina ;

Cucolo, Lisa ;

Lee, David S. M. ;

Pauken, Kristen E. ;

Huang, Alexander C. ;

Gangadhar, Tara C. ;

Amaravadi, Ravi K. ;

Schuchter, Lynn M. ;

Feldman, Michael D. ;

Ishwaran, Hemant ;

Vonderheide, Robert H. ;

Maity, Amit ;

Wherry, E. John ;

Minn, Andy J. .

CELL, 2016, 167 (06) :1540-+

[4] Easy quantitative assessment of genome editing by sequence trace decomposition [J].

Brinkman, Eva K. ;

Chen, Tao ;

Amendola, Mario ;

van Steensel, Bas .

NUCLEIC ACIDS RESEARCH, 2014, 42 (22)

[5] Novel cross-talk within the IKK family controls innate immunity [J].

Clark, Kristopher ;

Peggie, Mark ;

Plater, Lorna ;

Sorcek, Ronald J. ;

Young, Erick R. R. ;

Madwed, Jeffrey B. ;

Hough, Joanne ;

McIver, Edward G. ;

Cohen, Philip .

BIOCHEMICAL JOURNAL, 2011, 434 :93-104

[6] Inference of CRISPR Edits from Sanger Trace Data [J].

Conant, David ;

Hsiau, Tim ;

Rossi, Nicholas ;

Oki, Jennifer ;

Maures, Travis ;

Waite, Kelsey ;

Yang, Joyce ;

Joshi, Sahil ;

Kelso, Reed ;

Holden, Kevin ;

Enzmann, Brittany L. ;

Stoner, Rich .

CRISPR JOURNAL, 2022, 5 (01) :123-130

[7] Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1 [J].

Crew, Andrew P. ;

Raina, Kanak ;

Dong, Hanqing ;

Qian, Yimin ;

Wang, Jing ;

Vigil, Dominico ;

Serebrenik, Yevgeniy V. ;

Hamman, Brian D. ;

Morgan, Alicia ;

Ferraro, Caterina ;

Siu, Kam ;

Neklesa, Taavi K. ;

Winkler, James D. ;

Coleman, Kevin G. ;

Crews, Craig M. .

JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (02) :583-598

[8] Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor [J].

Deng, Rong ;

Bumbaca, Daniela ;

Pastuskovas, Cinthia V. ;

Boswell, C. Andrew ;

West, David ;

Cowan, Kyra J. ;

Chiu, Henry ;

McBride, Jacqueline ;

Johnson, Clarissa ;

Xin, Yan ;

Koeppen, Hartmut ;

Leabman, Maya ;

Iyer, Suhasini .

MABS, 2016, 8 (03) :593-603

[9] Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 [J].

Doench, John G. ;

Fusi, Nicolo ;

Sullender, Meagan ;

Hegde, Mudra ;

Vaimberg, Emma W. ;

Donovan, Katherine F. ;

Smith, Ian ;

Tothova, Zuzana ;

Wilen, Craig ;

Orchard, Robert ;

Virgin, Herbert W. ;

Listgarten, Jennifer ;

Root, David E. .

NATURE BIOTECHNOLOGY, 2016, 34 (02) :184-+

[10] Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation [J].

Doench, John G. ;

Hartenian, Ella ;

Graham, Daniel B. ;

Tothova, Zuzana ;

Hegde, Mudra ;

Smith, Ian ;

Sullender, Meagan ;

Ebert, Benjamin L. ;

Xavier, Ramnik J. ;

Root, David E. .

NATURE BIOTECHNOLOGY, 2014, 32 (12) :1262-U130

← 1 2 3 4 5 6 7 →